The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF
Abstract
Background The objective of the current study was to examine the efficacy and tolerability of the beta-blocker metoprolol succinate controlled release/extended release (CR/XL) in patients with diabetes in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).Methods The Cox proportional hazards model was used to calculate hazard ratios (HR) for convenience expressed as relative risks (risk reduction = 1-HR), and 95% confidence intervals (CI).Results The risk of hospitalization for heart failure was 76% higher in diabetics compared to non-diabetics (95% CI 38% to 123%). Metoprolol CR/XL was well tolerated and reduced the risk of hospitalization for heart failure by 37% in the diabetic group (95% CI 53% to 15%), and by 35% in the non-diabetic group (95% CI 48% to 19%). Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II (CIBIS II), MERIT-HF, and the Carvedilol Prospective Randomized Cumulative Survival Study (COPERNICUS) showed similar survival benefits in patients with diabetes (25%; 95% CI 40% to 4%) and without diabetes (36%; 95% CI 44% to 27%); test of diabetes by treatment interaction was non-significant. Adverse events were reported more often on placebo than on metoprolol CR/XL.Conclusions Patients with heart failure and diabetes have a much higher risk of hospitalization than patients without diabetes. Regardless of diabetic status, a highly significant reduction in hospitalizations for heart failure was observed with metoprolol CR/XL therapy, which was very well tolerated also by patients with diabetes. Furthermore, the pooled data showed a statistically significant survival benefit in patients with diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [37]
In the citing paper
“The highest prevalence of T2DM was seen in trials of acute HF (around 40%).”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [37]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [37]
In the citing paper
“Clinical trial results are somewhat conflicting regarding the risk of all-cause and CV mortality attributed to T2DM in HF patients, but most clinical trials reported an increased risk of death in patients with concurrent T2DM and HF (Table 5).1,31 -35,37,40,42,44,45,69,88-92”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [37]
In the citing paper
“Subgroup analyses of large HF trials show that beta-blockers reduce mortality and hospitalization and improve symptoms in moderate to severe HF, irrespectively of T2DM.37,152,153”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [37]
In the citing paper
“The MERIT-HF trial reported similar efficacy and safety of metoprolol succinate in patients with and ©2018 The Authors European Journal of Heart Failure ©2018 European Society of Cardiology without T2DM.37”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [37]
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
Lechat, P. P., Brunhuber, K., Hofmann, R., Kuhn, P., Nesser, H., Slany, J., Weihs, W., Wiedermann, C. J., Wimmer, H., van Mieghem, W., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11181-9 · Cited by 4,922
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,651
Malmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00126-k · Cited by 1,560
Cited by
Sorted by citations
Authors Task Force Members, Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,994
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,644
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-analysis
Emdin, C. A., Rahimi, K., Neal, B., Callender, T., Perkovic, V., & Patel, A. (2015) · JAMA · doi:10.1001/jama.2014.18574 · Cited by 854
Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708
Tsutsui, H., Isobe, M., Ito, H., Ito, H., Okumura, K., Ōno, M., Kitakaze, M., Kinugawa, K., Kihara, Y., Goto, Y., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0342 · Cited by 720
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000691 · Cited by 639
Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H., Huikuri, H., et al. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.10.013 · Cited by 609
Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure
Dei Cas, A., Khan, S. S., Butler, J., Mentz, R. J., Bonow, R. O., Avogaro, A., Tschoepe, D., Doehner, W., Greene, S. J., Senni, M., et al. (2015) · JACC Heart Failure · doi:10.1016/j.jchf.2014.08.004 · Cited by 401
Brunström, M., & Carlberg, B. (2016) · BMJ · doi:10.1136/bmj.i717 · Cited by 375
Reboldi, G., Gentile, G., Angeli, F., Ambrosio, G., Mancia, G., & Verdecchia, P. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283469976 · Cited by 275
Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline
Heart Failure Society of America (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.04.005 · Cited by 284
pre-diabetes Task Force on diabetes (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 239
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
MacDonald, M. R., Petrie, M. C., Hawkins, N. M., Petrie, J. R., Fisher, M., McKelvie, R., Aguilar, D., Krum, H., & McMurray, J. J. V. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn156 · Cited by 227
Greenberg, B. H., Abraham, W. T., Albert, N. M., Chiswell, K., Clare, R., Stough, W. G., Gheorghiade, M., O'Connor, C. M., Sun, J. L., Yancy, C. W., et al. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.05.001 · Cited by 196
Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis
Nasr, I. A., Bouzamondo, A., Hulot, J., Dubourg, O., Heuzey, J. Y. L., & Lechat, P. P. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl484 · Cited by 187
Dunlay, S. M., Givertz, M. M., Aguilar, D., Allen, L. A., Chan, M., Desai, A. S., Deswal, A., Dickson, V. V., Kosiborod, M. N., Lekavich, C. L., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.05.007 · Cited by 145
Wang, Q., Liu, Y., Fu, Q., Xu, B. Y., Zhang, Y., Kim, S., Tan, R., Barbagallo, F., West, T. M., Anderson, E. J., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.022281 · Cited by 120
Vonbach, P., Dubied, A., Krähenbühl, S., & Beer, J. H. (2008) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2007.12.002 · Cited by 117
The Real Role of β-Blockers in Daily Cardiovascular Therapy
Dézsi, C. A., & Szentes, V. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0221-8 · Cited by 117
The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma
Rothhammer-Hampl, T., Hahne, J. C., Florin, A., Poser, I., Soncin, F., Wernert, N., & Bosserhoff, A. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3337-8 · Cited by 110
Arnold, J. M. O., Howlett, J. G., Ducharme, A., Ezekowitz, J. A., Gardner, M. J., Giannetti, N., Haddad, H. A., Heckman, G. A., Isaac, D., Jong, P., et al. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)70545-2 · Cited by 103
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 92
Komajda, M., Tavazzi, L., Francq, B. G., Böhm, M., Borer, J. S., Ford, I., & Swedberg, K. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.347 · Cited by 76
Korean Guidelines for Diagnosis and Management of Chronic Heart Failure
Kim, M., Lee, J., Kim, E. J., Park, D.-G., Park, S., Park, J. J., Shin, M., Yoo, B., Youn, J., Lee, S. E., et al. (2017) · Korean Circulation Journal · doi:10.4070/kcj.2017.0009 · Cited by 76
Authors Task Force Members, Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M., Cosentino, F., Jönsson, B., Laakso, M., et al. (2007) · European Heart Journal Supplements · doi:10.1093/eurheartj/ehl261 · Cited by 76
Bell, D. S. H., Ann Lukas, M., Holdbrook, F. K., & Fowler, M. B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x80459 · Cited by 66
Hirst, J. A., Farmer, A. A., Feakins, B. G., Aronson, J. K., & Stevens, R. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12543 · Cited by 64
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L. L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
Parissis, J. T., Rafouli-Stergiou, P., Mebazaa, A., Ikonomidis, I., Bistola, V., Nikolaou, M., Meas, T., Delgado, J., Vilas-Boas, F., Paraskevaidis, I., et al. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.11.098 · Cited by 58
Molecular Mechanisms Responsible for Diastolic Dysfunction in Diabetes Mellitus Patients
Starčević, J. N., Janić, M., & Šabović, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051197 · Cited by 59
Diabetes Mellitus and Heart Failure
Tousoulis, D., Oikonomou, E. K., Siasos, G., & Stefanadis, C. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.1.37 · Cited by 55
Metabolic Effects of ??-Adrenoceptor Antagonists with Special Emphasis on Carvedilol
Kveiborg, B., Christiansen, B., Major‐Pedersen, A., & Torp-Pedersen, C. T. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606040-00001 · Cited by 52
Fonarow, G. C., & Srikanthan, P. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.05.003 · Cited by 52
Ghali, J. K., Boehmer, J., Feldman, A. M., Saxon, L. A., Demarco, T., Carson, P., Yong, P., Galle, E. G., Leigh, J., Ecklund, F. L., et al. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.06.723 · Cited by 50
Sudden cardiac death in patients with diabetes mellitus and chronic heart failure
Walker, A. M., & Cubbon, R. M. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115573225 · Cited by 47
Diabetic cardiomyopathy and diastolic heart failure – Difficulties with relaxation
Teupe, C., & Rosak, C. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.03.008 · Cited by 45
Hoppe, U. C., Freemantle, N., Cleland, J. G. F., Marijianowski, M., & Erdmann, E. (2007) · Diabetes Care · doi:10.2337/dc06-2035 · Cited by 43
Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control
Seferović, J. P., Solomon, S. D., & Seely, E. W. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820970444 · Cited by 41
Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy
Dannenberg, L., Weske, S., Kelm, M., Levkau, B., & Polzin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107920 · Cited by 40
de Boer, R. A., Doehner, W., van der Horst, I. C. C., Anker, S. D., Babalis, D., Roughton, M., Coats, A. J., Flather, M. D., & van Veldhuisen, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.02.018 · Cited by 39
Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME
Sarafidis, P. A., Lazaridis, A. A., Ruiz‐Hurtado, G., & Ruilope, L. M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.209 · Cited by 40
Nasir, S., & Aguilar, D. A. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.031 · Cited by 39
Gustafsson, F., Schou, M., Videbæk, L. M., Nielsen, T., Ulriksen, H., Markenvard, J., Svendsen, T. L., Ryde, H., Vigholt, E., & Hildebrandt, P. R. (2007) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.05.008 · Cited by 37
Kamalesh, M., & Cleophas, T. J. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.11.006 · Cited by 36
Type 2 Diabetes Mellitus and Heart Failure
Choy, C. K., Rodgers, J. E., Nappi, J. M., & Haines, S. T. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.2.170 · Cited by 34
Yang, Q., Zheng, R., Wang, S., Zhu, J., Li, M., Wang, T., Zhao, Z., Xu, M., Lu, J., Chen, Y., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.20954 · Cited by 36
Safety and tolerability of β-blockers: importance of cardioselectivity
Marti, H., López, A. A. P., & Schwartzmann, P. V. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2317433 · Cited by 32
Heart Failure in Diabetes and Related Conditions
Kamalesh, M. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.07.007 · Cited by 32
Pharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 33
(ESC), G. D. T. S. D. Y. E. C. D. L. S. E. D. C., & (EASD), D. L. S. E. P. E. E. D. L. D. (2007) · Revista Española de Cardiología · doi:10.1016/s0300-8932(07)75070-4 · Cited by 28
Jaime, J., Migliaccio–Walle, K., O’Brien, J. A., Nova, W., Kim, J., Hauch, O., Hillson, E., Wedel, H., Hjalmarson, Å. C., Gottlieb, S. S., et al. (2005) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2005.06.433 · Cited by 29
Comorbid Diabetes and End-of-Life Expenditures Among Medicare Beneficiaries With Heart Failure
Blecker, S., Herbert, R. J., & Brancati, F. L. (2011) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2011.09.011 · Cited by 28
Glucose Metabolism Abnormalities in Heart Failure Patients
Marsico, F., Gargiulo, P., Marra, A. M., Parente, A., & Paolillo, S. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.02.002 · Cited by 29
Underutilization of Evidence‐Based Therapies in Heart Failure: The Pharmacist's Role
Rodgers, J. E., & Stough, W. G. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.4part2.18s · Cited by 25
Go, Y. Y., Allen, J. C., Chia, S. Y., Sim, L. L., Jaufeerally, F. R., Yap, J. J. L., Ching, C. K., Sim, D., Kwok, B. W. K., & Liew, R. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.119 · Cited by 24
Metoprolol in the treatment of cardiovascular disease: a critical reappraisal
Grassi, G. M. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1479245 · Cited by 20
Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., Ishii, H., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0865 · Cited by 24
Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy
Butler, J., Januzzi, J. L., & Rosenstock, J. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14042 · Cited by 19
Chazova, I. E., Shestakova, M. V., Zhernakova, Y. V., Blinova, N. V., Маркова, Т. Н., Mazurina, N. V., Владиславович, Е. М., Tereshchenko, S. N., Жиров, И. В., Komarov, A. L., et al. (2021) · Eurasian heart journal · doi:10.38109/2225-1685-2021-2-6-61 · Cited by 19
Role of carvedilol controlled-release in cardiovascular disease
Fonarow, G. C. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.15 · Cited by 19
Fried, T. R., O’Leary, J. R., Towle, V. R., Goldstein, M. K., Trentelange, M., & Martin, D. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112593 · Cited by 19
Diabetes and Treatment of Chronic Heart Failure in a Large Real-World Heart Failure Population
Radhoe, S. P., Veenis, J. F., Linssen, G. C. M., van der Lee, C., Eurlings, L. W. M., Kragten, H. A., Al-Windy, N. Y. Y., van der Spank, A., Koudstaal, S., Rocca, H. B., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13743 · Cited by 16
Galis, P., Bartosova, L., Farkašová, V., Barteková, M., Ferenczyová, K., & Rajtík, T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1451100 · Cited by 19
Rydén, L., estable, G. D. T. D. L. S. E. D. C. S. D. Y. T. D. L. C. I., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H. P., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.10.015 · Cited by 20
the directors of the JCS, J., Araki, E., Tanaka, A., Inagaki, N., Ito, H., Ueki, K., Murohara, T., Imai, K., Sata, M., Sugiyama, T., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00471-5 · Cited by 16
Novel insight into the dangerous connection between diabetes and heart failure
Lombardi, C., Spigoni, V., Gorga, E., & Dei, A. (2016) · Herz · doi:10.1007/s00059-016-4415-7 · Cited by 17
Stecker, E. C., Fendrick, A. M., Knight, B. P., & Aaronson, K. D. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.007 · Cited by 17
Impact of QRS duration on left ventricular remodelling and survival in patients with heart failure
Straw, S., McGinlay, M., Gierula, J., Lowry, J. E., Paton, M. F., Cole, C. A., Drozd, M., Koshy, A. O., Müllens, W., Cubbon, R. M., et al. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001231 · Cited by 16
Pharmacological interventions for heart failure in people with chronic kidney disease
Ravani, P., Quinn, R. R., & Strippoli, G. F. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466 · Cited by 16
Risk of New-Onset Diabetes Mellitus in Patients With Hypertension Treated With Beta Blockers
Ram, C. V. S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.037 · Cited by 15
Diabetic Cardiomyopathy: An Update on Emerging Pathological Mechanisms
Kakkar, C., Sharma, V., Mannan, A., Gupta, G., Singh, S. K., Kumar, P., Dua, K., Kaur, A., Singh, S., Dhiman, S., et al. (2024) · Current Cardiology Reviews · doi:10.2174/011573403x331870241025094307 · Cited by 14
Blood pressure targets for hypertension in patients with type 2 diabetes
Aronow, W. S., & Shamliyan, T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.36 · Cited by 15
Glycemic control and treatment patterns in patients with heart failure
Tang, W. H. W. (2007) · Current Cardiology Reports · doi:10.1007/bf02938357 · Cited by 13
Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure
Sindaco, D. D., Pulignano, G., Cioffi, G., Tarantini, L., Lenarda, A. D., Feo, S. D., Opasich, C., Minardi, G., Giovannini, E., & Leggio, F. (2007) · Journal of Cardiovascular Medicine · doi:10.2459/01.jcm.0000285316.71057.26 · Cited by 13
GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES
Rydén, L., Standl, E., Bartnik, M., den Berghe, G. V., Betteridge, J. D., de Boer, M. J., Cosentino, F., Jönsson, B., Laakso, M., Malmberg, K., et al. (2007) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2007-3-5-88-111 · Cited by 13
GREGORIO, C. D., Micari, A., Grimaldi, P., Bragadeesh, T., Arrigo, F., & Coglitore, S. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.10.045 · Cited by 12
Abdin, A., Kondo, T., Böhm, M., Jhund, P. S., Claggett, B. L., Vaduganathan, M., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., Martínez, F. A., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3350 · Cited by 11
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Pharmacologic management of patients with both heart failure and diabetes
MacDonald, M. R., Petrie, M. C., Fisher, M., & McMurray, J. J. V. (2009) · Current Heart Failure Reports · doi:10.1007/s11897-009-0019-3 · Cited by 8
Double trouble: managing diabetic emergencies in patients with heart failure
Philip, L., & Poole, R. (2018) · Practical Diabetes · doi:10.1002/pdi.2181 · Cited by 8
Heart failure and diabetes mellitus: insight into comorbidity
Petunina, N. A., Викторович, Т. И., Trukhina, L. V., Sizova, Z. M., & Zakharova, V. L. (2019) · Diabetes Mellitus · doi:10.14341/dm9784 · Cited by 8
Schneider, C. A., Pfister, R., & Erdmann, E. (2010) · Herz · doi:10.1007/s00059-010-3337-z · Cited by 7
EASD, E. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0289 · Cited by 9
A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure
Iyngkaran, P., Toukhsati, S. R., Thomas, M. C., Jelinek, M. V., Hare, D. L., & Horowitz, J. D. (2016) · Clinical Medicine Insights Cardiology · doi:10.4137/cmc.s38444 · Cited by 7
Masarone, D., Pacileo, R., & Pacileo, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10189-4 · Cited by 7
Марданов, Б. У., Korneeva, M., & Akhmedova, E. B. (2016) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2016-12-6-743-748 · Cited by 6
Saqan, R., & Thiabat, H. A. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3720-6 · Cited by 6
Heart failure: A preventable and treatable complication of type 2 diabetes
Straw, S., Witte, K. K., & Kearney, M. T. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12930 · Cited by 6
Update on the Impact of Comorbidities on the Efficacy and Safety of Heart Failure Medications
Chow, C., Mentz, R. J., & Greene, S. J. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00512-3 · Cited by 6
Beta-adrenergic receptor blockade and pediatric dilated cardiomyopathy
Kaufman, B. D., & Shaddy, R. E. (2007) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2007.08.004 · Cited by 6
Positionspapier Herzinsuffizienz und Diabetes
Schütt, K. S., Aberle, J., Bauersachs, J. K., Birkenfeld, A. L., Frantz, S., Ganz, M., Jacob, S., Kellerer, M., Leschke, M., Liebetrau, C., et al. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1867-3026 · Cited by 5
Subramanian, U., Kamalesh, M., Temkit, M., Eckert, G. J., & Sawada, S. G. (2009) · American Journal of Cardiovascular Drugs · doi:10.2165/1006180-000000000-00000 · Cited by 5
Prevalent Diabetes Mellitus: Mortality and Management in Norwegian Heart Failure Outpatients
Stubnova, V., Os, I., Grundtvig, M., & Waldum-Grevbo, B. E. (2016) · Cardiology · doi:10.1159/000444658 · Cited by 5
Sodium–Glucose Cotransporter-2 Inhibition in Type 2 Diabetes Mellitus
Dalan, R. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000201 · Cited by 5
The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure
Freitas, O. D., Lenz, O., Fornoni, A., & Materson, B. J. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.2.139 · Cited by 5
Heart Failure in Diabetes Mellitus: An Updated Review
Sohrabi, C., Saberwal, B., Lim, W. Y., Tousoulis, D., Ahsan, S., & Παπαγεωργίου, Ν. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118091659 · Cited by 5
Pastormerlo, L. E., Mammini, C., Giannoni, A., Valleggi, A., Prontera, C., Gabutti, A., Poletti, R., Padeletti, L., Emdin, M., & Passino, C. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000159 · Cited by 4
Xu, H., Wang, Q., Liu, Y., Meng, L., Long, H., Wang, L., & Liu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.708581 · Cited by 4
Beta-receptor blockers in primary prevention for cardiovascular disease: forgotten benefits?
Nilsson, P. M., & Berglund, G. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002042 · Cited by 4
Metadata
- Authors
- Deedwania, P. C., Giles, T. D., Klibaner, M., Ghali, J. K., Herlitz, J., Hildebrandt, P., Kjekshus, J., Spinar, J., Vitovec, J., Stanbrook, H., & Wikstrand, J.
- Affiliations
- Veterans Health Administration (US)
- Louisiana State University (US)
- AstraZeneca (United States) (US)
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- Corresponding author
- Deedwania, Prakash C.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2005-01
- Volume
- 149
- Issue
- 1
- Pages
- 159-167
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W1980524591
- Cited by
- 143
- References
- 21
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 4 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 10 · 2018: 6 · 2017: 7 · 2016: 10 · 2015: 7 · 2014: 11 · 2013: 2 · 2012: 2
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- Borås Academic Digital Archive (University of Borås) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- metoprolol succinate, beta-blockers, chronic heart failure, diabetes mellitus, heart failure hospitalization, survival benefit, drug tolerability, adverse events, Copernicus
- MeSH terms
- Adrenergic beta-Antagonists, Adult, Aged, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Metoprolol, Middle Aged, Risk, Proportional Hazards Models, Survival Analysis, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
